LJ
Highly rated in
11
conditions
Highly rated in
11
conditions
Check Dr. Lesley A. Jarvis' experience treating your condition:
About Dr. Lesley A. Jarvis

Lesley Jarvis is a Radiation Oncologist in Lebanon, New Hampshire. Jarvis has been practicing medicine for over 19 years and is highly rated in 11 conditions, according to our data. Her top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma CTCL, Angiosarcoma, and Intraductal Papilloma. She is licensed to treat patients in New Hampshire. Jarvis is currently accepting new patients.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 4 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Lesley A. Jarvis it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Lesley A. Jarvis accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
Locations
1 Medical Center Dr, Lebanon, NH 03756
Background & Education
Graduate Institution
Stanford University School Of Medicine, 2003
Specialties
Radiation Oncology
Licenses
Radiology in NH
Hospital Affiliations
Dartmouth-Hitchcock Medical Center
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


4 Clinical Trials

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
View 2 Less Clinical Trial -

58 Total Publications

Epidermal growth factor-targeted fluorescence is unaffected by standard neoadjuvant therapies in human sarcomas.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors